[go: up one dir, main page]

UY37651A - Polipéptido de unión al il-1r-i - Google Patents

Polipéptido de unión al il-1r-i

Info

Publication number
UY37651A
UY37651A UY0001037651A UY37651A UY37651A UY 37651 A UY37651 A UY 37651A UY 0001037651 A UY0001037651 A UY 0001037651A UY 37651 A UY37651 A UY 37651A UY 37651 A UY37651 A UY 37651A
Authority
UY
Uruguay
Prior art keywords
polypeptide
union
present disclosure
binding
relates
Prior art date
Application number
UY0001037651A
Other languages
English (en)
Inventor
Joachim Feldwisch
Malin Lindborg
Joakim Nilsson
Erik Nordling
Robert Svensson
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of UY37651A publication Critical patent/UY37651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a una clase de polipéptidos genéticamente modificados que tienen una afinidad de unión por receptor de interleucina-1 de tipo I (IL-1R-I) que comprende el motivo de unión (BM) EX2X3X4X5X6X7EIX10X11LPNLX16RX18QYX21A FIX25X26LX28D. La presente divulgación también se refiere al uso de dicho polipéptido de unión al IL-1R-I como agente terapéutico, de pronóstico y/o de diagnóstico.
UY0001037651A 2017-03-31 2018-04-02 Polipéptido de unión al il-1r-i UY37651A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17164226 2017-03-31

Publications (1)

Publication Number Publication Date
UY37651A true UY37651A (es) 2018-10-31

Family

ID=58536721

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037651A UY37651A (es) 2017-03-31 2018-04-02 Polipéptido de unión al il-1r-i

Country Status (14)

Country Link
US (2) US12116397B2 (es)
EP (1) EP3601317A1 (es)
JP (2) JP2020515252A (es)
KR (1) KR102717131B1 (es)
CN (1) CN110650971A (es)
AR (1) AR111348A1 (es)
AU (1) AU2018242224B2 (es)
BR (1) BR112019019819A2 (es)
CA (1) CA3056985A1 (es)
IL (1) IL269477B2 (es)
MX (1) MX2019011191A (es)
SG (1) SG11201908274YA (es)
UY (1) UY37651A (es)
WO (1) WO2018178392A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
ES2319426T3 (es) * 2003-07-04 2009-05-07 Affibody Ab Polipeptidos que presentan afinidad de union por her-2.
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
EA200801170A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
CA2688433A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
EP3825329A1 (en) 2007-12-26 2021-05-26 Xencor, Inc. Fc variants with altered binding to fcrn
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
KR20130119990A (ko) * 2009-04-10 2013-11-01 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
DK2544785T3 (en) * 2010-03-08 2016-01-18 Ge Healthcare Bio Sciences Ab Immunoglobulin G Fc region binding polypeptide
CA2863862C (en) 2012-02-20 2021-03-16 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
WO2014064237A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Abd binding polypeptide
ES2660912T3 (es) 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
ES2842105T3 (es) * 2013-08-28 2021-07-12 Ipc Res Llc Polipéptidos estables que se unen a C5 de complemento humano
US10167322B2 (en) * 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
EP3154563B1 (en) 2014-06-13 2019-08-14 Affibody AB New polypeptide
WO2016059057A1 (en) * 2014-10-13 2016-04-21 Affibody Ab Vegfr-2 binding polypeptides
PL3245224T3 (pl) 2015-01-12 2021-01-25 Affibody Ab Polipeptydy wiążące il-17a
JP2023023582A (ja) * 2021-08-05 2023-02-16 栗田工業株式会社 感染症対策装置、プログラム、および感染症対策方法

Also Published As

Publication number Publication date
JP2020515252A (ja) 2020-05-28
EP3601317A1 (en) 2020-02-05
JP2023071776A (ja) 2023-05-23
AR111348A1 (es) 2019-07-03
IL269477B2 (en) 2024-06-01
IL269477A (en) 2019-11-28
SG11201908274YA (en) 2019-10-30
MX2019011191A (es) 2019-12-11
US12116397B2 (en) 2024-10-15
BR112019019819A2 (pt) 2020-04-22
AU2018242224B2 (en) 2021-09-02
IL269477B1 (en) 2024-02-01
CN110650971A (zh) 2020-01-03
CA3056985A1 (en) 2018-10-04
US20250066451A1 (en) 2025-02-27
WO2018178392A1 (en) 2018-10-04
US20210403533A1 (en) 2021-12-30
KR102717131B1 (ko) 2024-10-15
KR20190134617A (ko) 2019-12-04
AU2018242224A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
MX2016005689A (es) Celulas no t efectoras y madre/progenitoras hematopoyeticas modificadas y usos de estas.
BR112018010947A2 (pt) método utilizando complexo de proteína biespecífico
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
BR112018011008A2 (pt) agonistas de cnp de liberação controlada com ligação a npr-c baixa
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
BR112016010191A2 (pt) matriz de eluição e usos desta
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
CL2020000812A1 (es) Semaglutida en la terapia médica.
CU24453B1 (es) Anticuerpos anti proteína similar a angiopoyetina 4

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231026